Federal Register of Legislation - Australian Government

Primary content

PB 17 of 2012 Determinations/Health as made
This determination amends the National Health (Listed drugs on F1 or F2) Determination 2010 (No. PB 93 of 2010) to add two newly listed drugs, rilpivirine and tadalafil to F1 and also moves eight drugs from F1 to F2.
Administered by: Health
Registered 30 Mar 2012
Tabling HistoryDate
Tabled HR08-May-2012
Tabled Senate10-May-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

National Health (Listed drugs on F1 or F2) Amendment Determination 2012 (No.2)

Instrument number PB 17 of 2012

National Health Act 1953

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the
Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated                  27         March   2012

 

 

 

 

 

 

 

 

 

ADRIANA PLATONA

 

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health and Ageing

 

 

Part 1         Preliminary

1              Name of Determination

         (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2012 (No.2).

         (2)   This Determination may also be cited as PB 17 of 2012.

2              Commencement

                This Determination commences on 1 April 2012.

3              Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

                Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).


Schedule 1             Amendments

 

(Section 3)

 

 

[1]     Schedule 1, after item dealing with Anakinra

 

Omit

 

Anastrozole 

 

 

[2]     Schedule 1, after item dealing with Atomoxetine

 

Omit

 

Atorvastatin 

 

[3]     Schedule 1, after item dealing with Lenograstim

 

Omit

 

Letrozole 

 

[4]     Schedule 1, after item dealing with Mupirocin

 

Omit

 

Mycophenolic acid 

 

[5]     Schedule 1, after item dealing with Ofloxacin

 

Omit

 

Olanzapine 

 

[6]     Schedule 1, after item dealing with Pyrimethamine

 

Omit

 

Quetiapine 

 

[7]     Schedule 1, after item dealing with Rifampicin

 

Insert

 

Rilpivirine 

 

 


[8]     Schedule 1, after item dealing with Rosiglitazone

 

Omit

 

Rosuvastatin 

 

[9]     Schedule 1, after item dealing with Sunitinib

 

Insert

 

Tadalafil 

 

 

[10]   Schedule 1, after item dealing with Varenicline

 

Omit

 

Venlafaxine 

 

 

[11]   Schedule 2, after item dealing with Ampicillin

 

Insert

 

Anastrozole 

 

 

[12]   Schedule 2, after item dealing with Atenolol

 

Insert

 

Atorvastatin

 

[13]   Schedule 2, after item dealing with Lercanidipine

 

Insert

 

Letrozole

 

[14]   Schedule 2, after item dealing with Morphine

 

Insert

 

Mycophenolic acid

 

 

 

[15]   Schedule 2, after item dealing with Oestradiol

 

Insert

 

Olanzapine

 

[16]   Schedule 2, after item dealing with Prochlorperazine

 

Insert

 

Quetiapine

 

[17]   Schedule 2, after item dealing with Risperidone

 

Insert

 

Rosuvastatin

 

[18]   Schedule 2, after item dealing with Vancomycin

 

Insert

 

Venlafaxine

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Note

1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.